Signaturefd LLC Buys 51 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Signaturefd LLC raised its stake in United Therapeutics Co. (NASDAQ:UTHR) by 8.8% in the third quarter, Holdings Channel reports. The firm owned 633 shares of the biotechnology company’s stock after acquiring an additional 51 shares during the quarter. Signaturefd LLC’s holdings in United Therapeutics were worth $227,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of UTHR. Park Avenue Securities LLC lifted its position in shares of United Therapeutics by 11.0% in the first quarter. Park Avenue Securities LLC now owns 1,562 shares of the biotechnology company’s stock valued at $359,000 after buying an additional 155 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in United Therapeutics by 85.4% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 2,585 shares of the biotechnology company’s stock worth $594,000 after purchasing an additional 1,191 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in United Therapeutics by 14.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 3,291 shares of the biotechnology company’s stock worth $756,000 after purchasing an additional 413 shares during the last quarter. Compass Ion Advisors LLC lifted its holdings in United Therapeutics by 3.6% during the 1st quarter. Compass Ion Advisors LLC now owns 2,892 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 101 shares during the last quarter. Finally, Diversified Trust Co lifted its holdings in United Therapeutics by 286.6% during the 1st quarter. Diversified Trust Co now owns 5,045 shares of the biotechnology company’s stock worth $1,159,000 after purchasing an additional 3,740 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on UTHR. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 price objective on shares of United Therapeutics in a report on Thursday, August 1st. LADENBURG THALM/SH SH cut United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Oppenheimer lifted their price objective on United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a report on Wednesday, August 28th. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $310.00 to $321.00 in a report on Thursday, July 11th. Finally, UBS Group lifted their price target on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $361.33.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $45,293.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $45,293.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Raymond Dwek sold 5,000 shares of United Therapeutics stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $325.35, for a total value of $1,626,750.00. Following the transaction, the director now directly owns 1,750 shares in the company, valued at $569,362.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 102,812 shares of company stock worth $35,251,926 in the last 90 days. Insiders own 12.50% of the company’s stock.

United Therapeutics Trading Down 0.4 %

Shares of UTHR stock opened at $348.65 on Friday. The firm has a market capitalization of $15.46 billion, a P/E ratio of 16.48, a P/E/G ratio of 1.35 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $377.03. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $354.00 and its 200 day simple moving average is $312.79.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The firm had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company’s revenue was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.24 EPS. As a group, sell-side analysts predict that United Therapeutics Co. will post 24.72 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.